Century Therapeutics, Inc. is a pioneering biotechnology company focused on developing transformative allogeneic cell therapies. These therapies are designed to treat both hematological (blood-related) and solid tumor malignancies, addressing significant unmet medical needs in the healthcare sector. The company leverages a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells (iPSCs), advanced differentiation techniques to generate immune effector cells from iPSCs, and CRISPR-mediated precision gene editing.

Century Therapeutics operates primarily in the biotechnology and healthcare markets, serving patients with severe cancer conditions. The business model revolves around research and development (R&D) of innovative therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful therapies.

Keywords: allogeneic cell therapies, hematological malignancies, solid tumors, iPSCs, CRISPR, biotechnology, immune effector cells, cancer treatment, R&D, healthcare.